<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PRASCEND- pergolide mesylate tablet </strong><br>Boehringer Ingelheim Vetmedica, Inc.<br></p></div>
<h1>Prascend® (pergolide mesylate) Tablets, 1 mg</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_9ef8b948-2259-49a0-9a6c-a06379eccf5e"></a><a name="section-1"></a><p></p>
<p class="First">NADA 141-331, Approved by FDA</p>
<p>Dopamine receptor agonist for oral use in horses only</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_7e549618-f6e5-44b6-b18d-a7039fb6accb"></a><a name="section-2"></a><p></p>
<h1>Caution</h1>
<p class="First">Federal law restricts this drug to use by or on the order of a licensed veterinarian.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_87489107-a843-462c-9c36-8856a10cd7db"></a><a name="section-3"></a><p></p>
<h1>Description</h1>
<p class="First">Prascend Tablets are rectangular light red colored, half-scored tablets containing 1 mg pergolide, as pergolide mesylate. Pergolide mesylate is a synthetic ergot derivative and is a potent dopamine receptor agonist. The chemical name of pergolide mesylate is 8β-[(Methylthio) methyl]-6-propylergoline monomethanesulfonate.</p>
<p>The chemical structure is:</p>
<div class="Figure"><img alt="Picture of chemical structure." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=455e5d97-f639-472b-b93b-88b9174a0310&amp;name=455e5d97-f639-472b-b93b-88b9174a0310-01.jpg"></div>
</div>
<div class="Section" data-sectionCode="50745-9">
<a name="i4i_veterinary_indications_id_895c865c-f79e-4693-a9b4-13e10b730333"></a><a name="section-4"></a><p></p>
<h1>Indication</h1>
<p class="First">For the control of clinical signs associated with Pituitary Pars Intermedia Dysfunction (Equine Cushing’s Disease) in horses.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_4f492630-89a4-4229-b6b6-51a905cab86d"></a><a name="section-5"></a><p></p>
<h1>Dosage and Administration</h1>
<p class="First">Administer orally at a starting dose of 2 mcg/kg once daily. Dosage may be adjusted to effect, not to exceed 4 mcg/kg daily. It has been reported that pergolide tablets may cause <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>, an irritating smell, or <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> when Prascend Tablets are split or crushed. Prascend Tablets should not be crushed due to the potential for increased human exposure and care should be taken to minimize exposure when splitting tablets.</p>
<p>The tablets are scored and the calculated dosage should be provided to the nearest one-half tablet increment (see Table 1).</p>
<a name="id_7dae239e-c092-40f4-a29e-c979174327f5"></a><table width="256">
<caption><span>Table 1  Dosing Table</span></caption>
<col width="45.7%">
<col width="28.1%">
<col width="26.2%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Dosage</span></td>
<td class="Botrule Lrule" align="left" valign="top"><span class="Bold">Dosage</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Body weight</span></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">2 mcg/kg</span></td>
<td class="Botrule Lrule" align="left" valign="top"><span class="Bold">4 mcg/kg</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">136 - 340 kg</p>
<p>(300 - 749 lb)</p>
</td>
<td class="Botrule Rrule" align="left" valign="top">0.5 tablet</td>
<td class="Botrule Lrule" align="left" valign="top">1 tablet</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">341 - 567 kg</p>
<p>750 - 1,249 lb)</p>
</td>
<td class="Botrule Rrule" align="left" valign="top">1 tablet</td>
<td class="Botrule Lrule" align="left" valign="top">2 tablets</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">
<p class="First">568 - 795 kg</p>
<p>(1,250 - 1,749 lb)</p>
</td>
<td class="Botrule Rrule" align="left" valign="top">1.5 tablets</td>
<td class="Botrule Lrule" align="left" valign="top">3 tablets</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left" valign="top">
<p class="First">796 - 1,022 kg</p>
<p>(1,750 - 2,249 lb)</p>
</td>
<td class="Rrule" align="left" valign="top">2 tablets</td>
<td class="Botrule" align="left" valign="top">4 tablets</td>
</tr>
</tbody>
</table>
<p>Dosing should be titrated according to individual response to therapy to achieve the lowest effective dose. Dose titration is based on improvement in clinical signs associated with Pituitary Pars Intermedia Dysfunction (PPID) and/or improvement or normalization of endocrine tests (for example, <span class="product-label-link" type="condition" conceptid="4091300" conceptname="Dexamethasone suppression test">dexamethasone suppression test</span> or endogenous ACTH test). If signs of dose intolerance develop, the dose should be decreased by half for 3 to 5 days and then titrated back up in 2 mcg/kg increments every 2 weeks until the desired effect is achieved.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_00ac9b66-aa17-4a9a-87b8-d3d0befe8ed4"></a><a name="section-6"></a><p></p>
<h1>Contraindications</h1>
<p class="First">Prascend is contraindicated in horses with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to pergolide mesylate or other ergot derivatives.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_97e28766-db33-4ad2-ad5d-d609e626f707"></a><a name="section-7"></a><p></p>
<h1>Warnings</h1>
<p class="First">Do not use in horses intended for human consumption.</p>
</div>
<div class="Section" data-sectionCode="54433-8">
<a name="i4i_user_safety_id_3f079af9-e363-464c-9bd3-345fbf8159b6"></a><a name="section-8"></a><p></p>
<h1>Human Warnings</h1>
<p class="First"><span class="Bold">Not for use in humans. </span>Keep this and all medications out of the reach of children. Prascend should not be administered by persons who have had adverse reactions to ergotamine or other ergot derivatives. <span class="Bold">Pregnant or lactating women should wear gloves when administering this product. </span>It has been reported that pergolide tablets may cause <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>, an irritating smell, or <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> when Prascend Tablets are split or crushed. Prascend Tablets should not be crushed due to the potential for increased human exposure and care should be taken to minimize exposure when splitting tablets. Consult a physician in case of accidental ingestion by humans.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_7caa0b33-20fd-4c1f-a981-0bc793da1f2a"></a><a name="section-9"></a><p></p>
<h1>Precautions</h1>
<p class="First">Treatment with Prascend may cause inappetance.</p>
<p>The use of Prascend in breeding, pregnant, or lactating horses has not been evaluated. The effects of pergolide mesylate on breeding, pregnant, or lactating horses are not known; however, the pharmacologic action of pergolide mesylate suggests that it may interfere with reproductive functions such as lactation.</p>
<p>Prascend is approximately 90% associated with plasma proteins. Use caution if administering Prascend with other drugs that affect protein binding. Dopamine antagonists, such as neuroleptics (phenothiazines, domperidone) or metoclopramide, ordinarily should not be administered concurrently with Prascend (a dopamine agonist) since these agents may diminish the effectiveness of Prascend.</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_613bbee5-aad6-4188-8636-28163c30b73f"></a><a name="section-10"></a><p></p>
<h1>Adverse Reactions</h1>
<p class="First">A total of 122 horses treated with Prascend Tablets for six months were included in a field study safety analysis.</p>
<a name="id_6344fa74-2e6d-4e48-a73d-ffc55083d2d3"></a><table width="251">
<caption><span>Table 2  Summary of the most common adverse reactions(N=122)</span></caption>
<col width="48.6%">
<col width="24.7%">
<col width="26.7%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold">Clinical Sign</span></td>
<td class="Botrule Rrule" align="left" valign="top"><span class="Bold"># Cases</span></td>
<td class="Botrule Lrule" align="left" valign="top"><span class="Bold">Cases (%)</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Decreased appetite</span></td>
<td class="Botrule Rrule" align="center" valign="top">40</td>
<td class="Botrule Lrule" align="center" valign="top">32.8</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Lameness</td>
<td class="Botrule Rrule" align="center" valign="top">22</td>
<td class="Botrule Lrule" align="center" valign="top">18.0</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>/Loose stool</td>
<td class="Botrule Rrule" align="center" valign="top">12</td>
<td class="Botrule Lrule" align="center" valign="top">9.8</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Colic</span></td>
<td class="Botrule Rrule" align="center" valign="top">12</td>
<td class="Botrule Lrule" align="center" valign="top">9.8</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span></td>
<td class="Botrule Rrule" align="center" valign="top">12</td>
<td class="Botrule Lrule" align="center" valign="top">9.8</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Abnormal <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight Loss</span></td>
<td class="Botrule Rrule" align="center" valign="top">11</td>
<td class="Botrule Lrule" align="center" valign="top">9.0</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Laminitis*</td>
<td class="Botrule Rrule" align="center" valign="top">10</td>
<td class="Botrule Lrule" align="center" valign="top">8.2</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="316822" conceptname="Heart murmur">Heart murmur</span></td>
<td class="Botrule Rrule" align="center" valign="top">10</td>
<td class="Botrule Lrule" align="center" valign="top">8.2</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></td>
<td class="Botrule Rrule" align="center" valign="top">8</td>
<td class="Botrule Lrule" align="center" valign="top">6.6</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4122115" conceptname="Tooth disorder">Tooth disorder</span></td>
<td class="Botrule Rrule" align="center" valign="top">8</td>
<td class="Botrule Lrule" align="center" valign="top">6.6</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top">Skin <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span></td>
<td class="Botrule Rrule" align="center" valign="top">7</td>
<td class="Botrule Lrule" align="center" valign="top">5.7</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4150129" conceptname="Musculoskeletal pain">Musculoskeletal pain</span></td>
<td class="Botrule Rrule" align="center" valign="top">6</td>
<td class="Botrule Lrule" align="center" valign="top">4.9</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left" valign="top">Behavior change</td>
<td class="Rrule" align="center" valign="top">6</td>
<td class="Botrule" align="center" valign="top">4.9</td>
</tr>
</tbody>
</table>
<p>*Three new cases and 7 pre-existing, recurring cases</p>
<p>Inappetance or <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span> occurred at one or more meals in 40 of 122 horses treated with Prascend. At the baseline evaluation 1.6% of owners reported a history of inappetance or <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span> as compared to the 32.8% of horses that experienced inappetance or <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span> during the study. Most cases of inappetance were transient and occurred during the first month of treatment; however, some horses experienced sporadic inappetance throughout the study. Two horses required a temporary reduction in dose due to inappetance during the first month of the study. Both horses returned to their original dose within 30 days.</p>
<p><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight loss</span> occurred in more than half of the horses in this study; however, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span> that was considered abnormal was only reported in 11 horses.</p>
<p><span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">Lethargy</span> was reported in 9.8% of horses during the study, and was not reported in any horses at the baseline evaluation.</p>
<p>Behavioral changes were noted in 6 horses including <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggression</span>, kicking, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, nervous behavior and <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">increased activity</span>. One horse required a temporary reduction in dose due to energetic behavior during the first month of the study.</p>
<p>Eight horses died or were euthanized during the study due to worsening of pre-existing conditions (laminitis, dental disease, septic <span class="product-label-link" type="condition" conceptid="4195698" conceptname="Tenosynovitis">tenosynovitis</span>) or <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">colic</span> (strangulating <span class="product-label-link" type="condition" conceptid="440358" conceptname="Lipoma">lipomas</span>, large colon <span class="product-label-link" type="condition" conceptid="197603" conceptname="Intestinal volvulus">volvulus</span>).</p>
<p>One mare was inadvertently enrolled in the study while pregnant and experienced dystocia resulting in the <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of the foal.</p>
<p>To report suspected adverse reactions, to obtain a Material Safety Data Sheet (MSDS), or for technical assistance, call 1-866-638-2226.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_5a0bc583-342d-47f2-abfb-873132565632"></a><a name="section-11"></a><p></p>
<h1>Clinical Pharmacology</h1>
<p class="First">Pergolide mesylate is a synthetic ergot derivative and is a potent dopamine receptor agonist. As with other dopamine agonists, pergolide inhibits the release of prolactin which suggests that it may interfere with lactation. In horses with PPID, pergolide is believed to exert its therapeutic effect by stimulating dopamine receptors, and has been shown to decrease the plasma levels of adrenocorticotropic hormone (ACTH), melanocyte stimulating hormone (MSH), and other pro-opiomelanocortin peptides.<span class="Sup">1</span></p>
<p>Pharmacokinetic information in the horse is based on a study using single oral doses of 10 mcg/kg in six healthy mares between 3 and 17 years of age.<span class="Sup">2 </span>  Pergolide was rapidly absorbed; the mean maximum concentration (Cmax) was 4.05±2.02 ng/mL with the median time to maximum concentration (Tmax) being 0.415 hours.</p>
<p>The area under the curve (AUC) was 14.08±7.46 hr∙ng/mL. The mean half life (T1/2) was 5.86±3.42 hours; the mean apparent oral clearance (CL/F) was 1204 mL/kg/hr; and the mean apparent volume of distribution (V/F) was 3082±1354 mL/kg.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="i4i_clinical_studies_id_93e31da2-93c4-4628-b32c-cfba41c0f8ea"></a><a name="section-12"></a><p></p>
<h1>Effectiveness</h1>
<p class="First">An open-label, historical control, field study evaluated the effectiveness of Prascend for the control of clinical signs of PPID. A total of 122 horses with PPID were enrolled in the study, 113 of which were included in effectiveness evaluations. The success of each horse was based on results of endocrinology testing (<span class="product-label-link" type="condition" conceptid="4091300" conceptname="Dexamethasone suppression test">dexamethasone suppression test</span> or endogenous ACTH test) and/or improvement in clinical signs related to PPID (<span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">hyperhidrosis</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>/polydypsia, abnormal fat distribution, and/or <span class="product-label-link" type="condition" conceptid="78236" conceptname="Muscle atrophy">muscle wasting</span>) on the Day 180 evaluation. Based on endocrine testing and investigators' clinical assessment scores, 86 (76.1%) of the 113 evaluable cases were treatment successes.</p>
<a name="id_fe38e24f-49dd-4571-9c9a-2aa74311be4b"></a><table width="261">
<caption><span>Table 3  Proportion of Treatment Successes on Day 180</span></caption>
<col width="39.8%">
<col width="60.2%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Percent Success</span></td>
<td class="Botrule Lrule" align="center" valign="top"><span class="Bold">Lower bound: one-sided                             95% confidence interval</span></td>
</tr>
<tr class="Last">
<td class="Rrule" align="center" valign="top">76.1% (86/113)</td>
<td class="Botrule" align="center" valign="top">68.6%</td>
</tr>
</tbody>
</table>
<p>Enrolled horses were diagnosed with PPID based on the presence of <span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">hirsutism</span> and an abnormal pre-study endocrine test result. All horses were treated with 2 mcg/kg Prascend (to the nearest one-half tablet) orally once daily for the first three months. If the endocrine test result on Day 90 was normal or adequately improved, the horse continued on the same dose through Day 180. If the endocrine test result on Day 90 was abnormal, the dose increased to 4 mcg/kg given once daily through Day 180. Forty-seven (41.6%) of the 113 horses included in the effectiveness database required a dose increase at Day 90.</p>
<p>Improvement was noted in scores for all clinical sign categories and in mean results for endocrine tests.</p>
<a name="id_c7b2fd26-088c-4921-94e4-ebe164ec5dbb"></a><table width="0.000">
<caption><span>Table 4  Percent of Animals with Improvement in Clinical Signs Relative to Baseline Scores</span></caption>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Clinical Sign</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Day 90±7 (%)</span></td>
<td class="Botrule Lrule" align="center" valign="top"><span class="Bold">Day 180±7 (%)</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><span class="product-label-link" type="condition" conceptid="134718" conceptname="Hirsutism">Hirsutism</span></td>
<td class="Botrule Rrule" align="center" valign="top">32.7%</td>
<td class="Botrule Lrule" align="center" valign="top">89.2%</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Hyperhidrosis</span></td>
<td class="Botrule Rrule" align="center" valign="top">27.4%</td>
<td class="Botrule Lrule" align="center" valign="top">42.3%</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top"><span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">Polyuria</span>/polydypsia</td>
<td class="Botrule Rrule" align="center" valign="top">31.0%</td>
<td class="Botrule Lrule" align="center" valign="top">34.2%</td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top">Abnormal fat distribution</td>
<td class="Botrule Rrule" align="center" valign="top">21.2%</td>
<td class="Botrule Lrule" align="center" valign="top">33.3%</td>
</tr>
<tr class="Last">
<td class="Rrule" align="center" valign="top"><span class="product-label-link" type="condition" conceptid="78236" conceptname="Muscle atrophy">Muscle wasting</span></td>
<td class="Rrule" align="center" valign="top">36.3%</td>
<td class="Botrule" align="center" valign="top">46.0%</td>
</tr>
</tbody>
</table>
<a name="id_b8a3dcd9-b526-49ff-8f66-90e9f36b2bb3"></a><table width="0.000">
<caption><span>Table 5  Endocrine test results (mean values)</span></caption>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Test</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold"># Animals</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Baseline</span></td>
<td class="Botrule Rrule" align="center" valign="top"><span class="Bold">Day 90</span></td>
<td class="Botrule Lrule" align="center" valign="top"><span class="Bold">Day 180</span></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">ACTH</p>
<p> (pg/mL)</p>
</td>
<td class="Botrule Rrule" align="center" valign="top">20</td>
<td class="Botrule Rrule" align="center" valign="top">73.53</td>
<td class="Botrule Rrule" align="center" valign="top">51.12</td>
<td class="Botrule Lrule" align="center" valign="top">45.08</td>
</tr>
<tr class="Last">
<td class="Rrule" align="center" valign="top">
<p class="First">DST**</p>
<p>(mcg/dL)</p>
</td>
<td class="Rrule" align="center" valign="top">93</td>
<td class="Rrule" align="center" valign="top">3.12</td>
<td class="Rrule" align="center" valign="top">1.39</td>
<td class="Botrule" align="center" valign="top">1.47</td>
</tr>
</tbody>
</table>
<p>*<span class="product-label-link" type="condition" conceptid="4091300" conceptname="Dexamethasone suppression test">Dexamethasone suppression test</span>: Post dexamethasone cortisol concentration</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="i4i_animal_pharmacology_id_0428f69c-2e56-4198-a886-dc6454e30c41"></a><a name="section-13"></a><p></p>
<h1>Animal Safety</h1>
<p class="First">In a six month target animal safety study healthy adult horses received Prascend administered orally, once daily, at doses of either 0 mcg/kg, 4 mcg/kg, 6 mcg/kg, or 8 mcg/kg (0X, 1X, 1.5X, or 2X the maximum recommended dose). There were eight healthy horses (four males and four females) in each treatment group. Doses were prepared by dissolving tablets in approximately 10 mL of a 50% sugar water solution.</p>
<p>Prascend treated groups had lower mean heart rates and higher mean temperatures than the control group. Horses in all treatment groups had minimum heart rates within the normal range and maximum temperatures below 101.5°F. One 1.5X horse experienced a mild episode of spasmodic <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">colic</span> on Day 3 that resolved after treatment with flunixin meglumine.</p>
<p>Mean red blood cell counts and hemoglobin values were lower in Prascend treated groups as compared to the control group. Other hematology parameters including hematocrit, white blood cells, absolute <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span>, and absolute <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> exhibited mild, transient decreases as compared to the control group. The hematology parameters generally decreased over the first 30 to 60 days after treatment initiation and then returned to values similar to pre-treatment levels. No treatment related alterations were identified on histopathology evaluation of bone marrow.</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_storage_id_915c4c0a-bd3b-4911-8b67-f2f853d14df0"></a><a name="section-14"></a><p></p>
<h1>Storage</h1>
<p class="First">Store at or below 25°C (77°F).</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_c443b1f6-6d84-48f8-8426-91eb2e405cc7"></a><a name="section-15"></a><p></p>
<h1>How Supplied</h1>
<p class="First">Prascend (pergolide mesylate) Tablets are available in 1 mg strength – packaged 10 tablets per <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> and 60 or 160 tablets per carton.</p>
<p>NDC 0010-4489-01 – 60 tablets</p>
<p>NDC 0010-4489-02 – 160 tablets</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="i4i_references_id_d9c50939-e912-4f6c-844b-b7c42ae184c8"></a><a name="section-16"></a><p></p>
<h1>References</h1>
<p class="First"><span class="Sup">1</span> Orth, D.N., Holscher, M.A., Wilson, M.G., et al. (1982) Equine Cushing’s Disease: Plasma Immunoreactive Proopiolipomelanocortin Peptide and Cortisol Levels Basally and in Response to Diagnostic Tests. Endocrinology. 110(4):1430-41</p>
<p><span class="Sup">2</span> Wright A, Gehring R, Coetzee H (2008.) Pharmacokinetics of pergolide in normal mares. American College of Veterinary Internal Medicine Forum, Abstract #36, San Antonio, TX.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e8b3452e-125f-487b-ba89-5ae64898835c"></a><a name="section-17"></a><p></p>
<p class="First">Manufactured for:<br><span class="Bold">Boehringer Ingelheim Vetmedica, Inc.</span><br>St. Joseph, MO 64506 U.S.A.</p>
<p>Made in Japan and packaged in Germany.</p>
<p>Prascend is a registered trademark of Boehringer Ingelheim Vetmedica GmbH used under license.</p>
<p>© 2011 Boehringer Ingelheim Vetmedica, Inc. All Rights Reserved.</p>
<p>448901-00</p>
<p>Code 448911, 448921</p>
<p>Revised 07/2011</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_e607ea52-c199-42d6-9817-50a8a84cee8b"></a><a name="section-18"></a><p></p>
<h1>10-Tablet <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Pack</h1>
<div class="Figure"><img alt="Picture of front and side panel of 60-tablet display carton." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=455e5d97-f639-472b-b93b-88b9174a0310&amp;name=455e5d97-f639-472b-b93b-88b9174a0310-02.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_942b3d6c-ddfc-4282-9d4e-13a9424d174d"></a><a name="section-19"></a><p></p>
<h1>60-Tablet Display Carton</h1>
<div class="Figure">
<img alt="Picture of front and side of 60 tablet display carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=455e5d97-f639-472b-b93b-88b9174a0310&amp;name=455e5d97-f639-472b-b93b-88b9174a0310-03.jpg"><p class="MultiMediaCaption">Front and side panel</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_1c3e7053-6b47-4c3d-bee9-c5d5e3ff34ad"></a><a name="section-20"></a><p></p>
<h1><span class="Bold">60-Tablet Display Carton</span></h1>
<div class="Figure">
<img alt="Picture of back and side of 60 tablet carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=455e5d97-f639-472b-b93b-88b9174a0310&amp;name=455e5d97-f639-472b-b93b-88b9174a0310-04.jpg"><p class="MultiMediaCaption">Back and 2nd side panel</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_1410093f-3a07-43f3-9458-79d322cf3e91"></a><a name="section-21"></a><p></p>
<h1>160-Tablet Display Carton</h1>
<div class="Figure">
<img alt="Picture of front and side of 160 tablet carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=455e5d97-f639-472b-b93b-88b9174a0310&amp;name=455e5d97-f639-472b-b93b-88b9174a0310-05.jpg"><p class="MultiMediaCaption">Front and side panel</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_3023d4b8-be33-4828-aa70-51f8fb78a75b"></a><a name="section-22"></a><p></p>
<h1><span class="Bold">160-Tablet Display Carton</span></h1>
<div class="Figure">
<img alt="Picture of back and side of 160 tablet carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=455e5d97-f639-472b-b93b-88b9174a0310&amp;name=455e5d97-f639-472b-b93b-88b9174a0310-06.jpg"><p class="MultiMediaCaption">Back and 2nd side panel</p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PRASCEND 		
					</strong><br><span class="contentTableReg">pergolide mesylate tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">PRESCRIPTION ANIMAL DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0010-4489</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PERGOLIDE MESYLATE</strong> (PERGOLIDE) </td>
<td class="formItem">PERGOLIDE</td>
<td class="formItem">1 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED (Light red) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">RECTANGLE</td>
<td class="formLabel">Size</td>
<td class="formItem">12mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">PRD</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0010-4489-01</td>
<td class="formItem">6  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0010-4489-02</td>
<td class="formItem">16  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NADA</td>
<td class="formItem">NADA141331</td>
<td class="formItem">10/25/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Boehringer Ingelheim Vetmedica, Inc.
							(007134091)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 10/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>455e5d97-f639-472b-b93b-88b9174a0310</div>
<div>Set id: 455e5d97-f639-472b-b93b-88b9174a0310</div>
<div>Version: 1</div>
<div>Effective Time: 20111026</div>
</div>
</div> <div class="DistributorName">Boehringer Ingelheim Vetmedica, Inc.</div></p>
</body></html>
